| 4001 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2021 |
Standard Therapy |
Poland |
26 |
| 4002 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2021 |
Standard Therapy |
Poland |
56 |
| 4003 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2021 |
Standard Therapy |
Poland |
63 |
| 4004 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2021 |
Standard Therapy |
Poland |
61 |
| 4005 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2021 |
Standard Therapy |
Poland |
70 |
| 4006 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2021 |
Standard Therapy |
Poland |
66 |
| 4007 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2021 |
Standard Therapy |
Germany |
48 |
| 4008 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2021 |
Standard Therapy |
Germany |
58 |
| 4009 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2021 |
Standard Therapy |
Germany |
59 |
| 4010 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2021 |
Standard Therapy |
Poland |
62 |
| 4011 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2021 |
Standard Therapy |
Poland |
63 |
| 4012 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2021 |
Standard Therapy |
Poland |
64 |
| 4013 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2021 |
Standard Therapy |
Poland |
66 |
| 4014 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2021 |
Standard Therapy |
Poland |
65 |
| 4015 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2021 |
Standard Therapy |
Poland |
56 |
| 4016 |
Apheresis |
Allogeneic |
Myelofibrosis With Myeloid Metaplasia |
Hematology |
2021 |
Standard Therapy |
Poland |
75 |
| 4017 |
Apheresis |
Allogeneic |
Myelofibrosis With Myeloid Metaplasia |
Hematology |
2021 |
Standard Therapy |
Poland |
65 |
| 4018 |
Apheresis |
Allogeneic |
Myelofibrosis With Myeloid Metaplasia |
Hematology |
2021 |
Standard Therapy |
Poland |
51 |
| 4019 |
Apheresis |
Allogeneic |
Myelofibrosis With Myeloid Metaplasia |
Hematology |
2021 |
Standard Therapy |
Poland |
63 |
| 4020 |
Apheresis |
Allogeneic |
Myelofibrosis With Myeloid Metaplasia |
Hematology |
2021 |
Standard Therapy |
Poland |
75 |
| 4021 |
Apheresis |
Allogeneic |
Myelofibrosis With Myeloid Metaplasia |
Hematology |
2021 |
Standard Therapy |
Poland |
64 |
| 4022 |
Apheresis |
Allogeneic |
Myeloma Multiplex |
Hematology |
2021 |
Standard Therapy |
Poland |
48 |
| 4023 |
Apheresis |
Allogeneic |
Myeloma Multiplex |
Hematology |
2021 |
Standard Therapy |
Poland |
53 |
| 4024 |
Apheresis |
Allogeneic |
Myeloproliferative Neoplasms |
Hematology |
2021 |
Standard Therapy |
Poland |
67 |
| 4025 |
Apheresis |
Allogeneic |
Myeloproliferative Neoplasms |
Hematology |
2021 |
Standard Therapy |
Poland |
58 |
| 4026 |
Apheresis |
Allogeneic |
Myeloproliferative Neoplasms |
Hematology |
2021 |
Standard Therapy |
Germany |
51 |
| 4027 |
Apheresis |
Allogeneic |
No Data |
Hematology |
2021 |
Standard Therapy |
Poland |
64 |
| 4028 |
Apheresis |
Allogeneic |
No Data |
Hematology |
2021 |
Standard Therapy |
Poland |
57 |
| 4029 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Poland |
30 |
| 4030 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Poland |
51 |
| 4031 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Poland |
58 |
| 4032 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Poland |
56 |
| 4033 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Poland |
58 |
| 4034 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Poland |
50 |
| 4035 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Poland |
53 |
| 4036 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Poland |
20 |
| 4037 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Poland |
64 |
| 4038 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Poland |
66 |
| 4039 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
62 |
| 4040 |
Apheresis |
Autologous |
Non-Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
61 |
| 4041 |
Apheresis |
Autologous |
Non-Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
49 |
| 4042 |
Apheresis |
Allogeneic |
Non-Hodgkin-Lymphoma-Relapse |
Hematology |
2021 |
Standard Therapy |
Germany |
62 |
| 4043 |
Apheresis |
Allogeneic |
Osteomyelitis |
Hematology |
2021 |
Standard Therapy |
Poland |
47 |
| 4044 |
Apheresis |
Allogeneic |
Osteomyelofibrosis |
Hematology |
2021 |
Standard Therapy |
Poland |
69 |
| 4045 |
Apheresis |
Allogeneic |
Osteomyelofibrosis |
Hematology |
2021 |
Standard Therapy |
Poland |
43 |
| 4046 |
Apheresis |
Autologous |
Osteosclerotic Myeloma |
Hematology |
2021 |
Standard Therapy |
Germany |
54 |
| 4047 |
Apheresis |
Allogeneic |
Other Myelodysplastic Syndromes |
Hematology |
2021 |
Standard Therapy |
Poland |
65 |
| 4048 |
Apheresis |
Allogeneic |
Other Myelofibrosis |
Hematology |
2021 |
Standard Therapy |
Poland |
68 |
| 4049 |
Apheresis |
Allogeneic |
Other Myelofibrosis |
Hematology |
2021 |
Standard Therapy |
Poland |
70 |
| 4050 |
Apheresis |
Allogeneic |
Other Myelofibrosis |
Hematology |
2021 |
Standard Therapy |
Poland |
72 |
| 4051 |
Apheresis |
Allogeneic |
Other Plasma Cell Disorder |
Hematology |
2021 |
Standard Therapy |
Poland |
67 |
| 4052 |
Apheresis |
Allogeneic |
Peripheral T-Cell Lymphoma |
Hematology |
2021 |
Standard Therapy |
Poland |
45 |
| 4053 |
Apheresis |
Allogeneic |
Philadelphia-Positive Acute Lymphoblastic Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
61 |
| 4054 |
Apheresis |
Allogeneic |
Polycythemia Vera |
Hematology |
2021 |
Standard Therapy |
Poland |
65 |
| 4055 |
Apheresis |
Autologous |
Primary Central Nervous System Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
71 |
| 4056 |
Apheresis |
Autologous |
Primary Central Nervous System Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
66 |
| 4057 |
Apheresis |
Autologous |
Primary Central Nervous System Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
62 |
| 4058 |
Apheresis |
Autologous |
Primary Central Nervous System Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
53 |
| 4059 |
Apheresis |
Autologous |
Primary Central Nervous System Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
44 |
| 4060 |
Apheresis |
Autologous |
Primary Central Nervous System Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
54 |
| 4061 |
Apheresis |
Autologous |
Primary Central Nervous System Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
65 |
| 4062 |
Apheresis |
Autologous |
Primary Central Nervous System Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
65 |
| 4063 |
Apheresis |
Autologous |
Primary Central Nervous System Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
60 |
| 4064 |
Apheresis |
Allogeneic |
Primary Myelofibrosis |
Hematology |
2021 |
Standard Therapy |
Poland |
66 |
| 4065 |
Apheresis |
Allogeneic |
Primary Myelofibrosis |
Hematology |
2021 |
Standard Therapy |
Poland |
63 |
| 4066 |
Apheresis |
Allogeneic |
Primary Myelofibrosis |
Hematology |
2021 |
Standard Therapy |
Poland |
62 |
| 4067 |
Apheresis |
Allogeneic |
Primary Myelofibrosis |
Hematology |
2021 |
Standard Therapy |
Poland |
64 |
| 4068 |
Apheresis |
Allogeneic |
Prolymphocytic Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
68 |
| 4069 |
Apheresis |
Allogeneic |
Prolymphocytic Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
64 |
| 4070 |
Apheresis |
Allogeneic |
Refractory Cytopenia |
Hematology |
2021 |
Standard Therapy |
Poland |
6 |
| 4071 |
Apheresis |
Allogeneic |
Secondary Acute Lymphoblastic Leukemia From Chronic Myeloid Leukemia |
Hematology |
2021 |
Standard Therapy |
Poland |
58 |
| 4072 |
Apheresis |
Allogeneic |
Secondary Acute Myeloid Leukemia |
Hematology |
2021 |
Standard Therapy |
Germany |
70 |
| 4073 |
Apheresis |
Allogeneic |
Secondary Acute Myeloid Leukemia |
Hematology |
2021 |
Standard Therapy |
Germany |
64 |
| 4074 |
Apheresis |
Allogeneic |
Secondary Acute Myeloid Leukemia |
Hematology |
2021 |
Standard Therapy |
Germany |
39 |
| 4075 |
Apheresis |
Allogeneic |
Secondary Acute Myeloid Leukemia |
Hematology |
2021 |
Standard Therapy |
Germany |
60 |
| 4076 |
Apheresis |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2021 |
Standard Therapy |
Poland |
35 |
| 4077 |
Apheresis |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2021 |
Standard Therapy |
Poland |
58 |
| 4078 |
Apheresis |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2021 |
Standard Therapy |
Poland |
41 |
| 4079 |
Apheresis |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2021 |
Standard Therapy |
Poland |
38 |
| 4080 |
Apheresis |
Allogeneic |
Severe Combined Immunodeficiency |
Hematology |
2021 |
Standard Therapy |
Poland |
1 |
| 4081 |
Apheresis |
Allogeneic |
Severe Combined Immunodeficiency |
Hematology |
2021 |
Standard Therapy |
Poland |
1 |
| 4082 |
Apheresis |
Allogeneic |
T-Cell Lymphoblastic Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
26 |
| 4083 |
Apheresis |
Allogeneic |
T-Cell Lymphoblastic Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
37 |
| 4084 |
Apheresis |
Autologous |
T-Cell Non-Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
54 |
| 4085 |
Apheresis |
Autologous |
T-Cell Non-Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
66 |
| 4086 |
Apheresis |
Autologous |
T-Cell Non-Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
66 |
| 4087 |
Apheresis |
Autologous |
T-Cell Non-Hodgkin Lymphoma |
Hematology |
2021 |
Standard Therapy |
Germany |
29 |
| 4088 |
Apheresis |
Allogeneic |
T-Cell-Lymphoma |
Hematology |
2021 |
Standard Therapy |
Poland |
45 |
| 4089 |
Apheresis |
Autologous |
Testicular Cancer |
Hematology |
2021 |
Standard Therapy |
Germany |
33 |
| 4090 |
Apheresis |
Allogeneic |
Β – Thalassemia |
Hematology |
2021 |
Standard Therapy |
Poland |
17 |
| 4091 |
Adipose Tissue |
Autologous |
Gonarthrosis |
Orthopedy |
2021 |
Experimental Therapy |
Poland |
51,1 |
| 4092 |
Adipose Tissue |
Autologous |
Gonarthrosis |
Orthopedy |
2021 |
Experimental Therapy |
Poland |
44,4 |
| 4093 |
Adipose Tissue |
Autologous |
Gonarthrosis |
Orthopedy |
2021 |
Experimental Therapy |
Poland |
35,8 |
| 4094 |
Adipose Tissue |
Autologous |
Internal Damage To The Knee Joint |
Orthopedy |
2021 |
Experimental Therapy |
Poland |
40.9 |
| 4095 |
Adipose Tissue |
Autologous |
Soft Tissue Diseases Related To Use, Overload And Pressure |
Orthopedy |
2021 |
Experimental Therapy |
Poland |
27,5 |
| 4096 |
Placenta blood |
Autologous |
Cerebral Palsy |
Neurology |
2020 |
Experimental Therapy |
Poland |
2,6 |
| 4097 |
Cord Tissue |
Allogeneic – Unrelated |
Covid-19 |
Pulmonology |
2020 |
Experimental Therapy |
Poland |
84,5 |
| 4098 |
Cord Tissue |
Allogeneic – Unrelated |
Acquired Epileptic Aphasia |
Neurology |
2020 |
Experimental Therapy |
Poland |
4,11 |
| 4099 |
Cord Tissue |
Allogeneic – Unrelated |
Acute Graft Versus Host Disease |
Hematology |
2020 |
Experimental Therapy |
Poland |
8,11 |
| 4100 |
Cord Tissue |
Allogeneic – Unrelated |
Acute Graft Versus Host Disease |
Hematology |
2020 |
Experimental Therapy |
Poland |
8 |